Improving the Standard of Care in Community-Based HER2-Positive Metastatic Breast Cancer

Improving the Standard of Care in Community-Based HER2-Positive Metastatic Breast Cancer

Improving the Standard of Care in Community-Based HER2-Positive Metastatic Breast Cancer
RestartResume

Better therapeutics are emerging in the mBC space. This case-based discussion can help you fine-tune your treatment decisions and stay up to date.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    HER2 is overexpressed and/or amplified in about 20% of breast cancers and signifies aggressive tumor behavior. New anti-HER2 therapies are improving the outlook for advanced or metastatic disease with targeted therapeutics, but while physicians now have a multitude of therapies to choose from, patient-specific characteristics and sequencing still present a challenge.

    Tune in to enhance your knowledge and skills with this lively panel discussion examining 2 different patient cases with metastatic breast cancer (mBC). Explore optimal treatment selection based on patient-specific characteristics and ensure that you’re keeping up with the rapidly evolving landscape of HER2+ mBC. Find out what changes can make in your practice today to improve the lives of your patients.

    Note that this program follows a previous case-based simulation activity titled “Improving the Standard of Care in Community-Based HER2-Positive Metastatic Breast Cancer.” This panel discussion analyzes choices made in that simulation and expands on optimal recommendations. If you haven’t participated in the simulation and would like to put yourself to the test, you can find the link to the activity in the related section. 

    Since the recording of this interview, additional data have been released specific to efficacy in certain patient subgroups. To learn more about this data, please visit here.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    William J. Gradishar, MD, FASCO, FACP
    Betsy Bramsen Professor of Breast Oncology & Professor of Medicine
    Chief, Division of Hematology/Oncology
    Director, Maggie Daley Center for Women's Cancer Care
    Deputy Director, Clinical Network
    Robert H. Lurie Comprehensive Cancer Center of Northwestern University
    Northwestern University Feinberg School of Medicine
    Chicago, IL

    Consulting Fees: DMC-Seattle Genetics, Daiichi, Genentech, Immunomedics
    Research: Genentech, Roche

    Sara A. Hurvitz, MD, FACP
    Professor of Medicine
    Director, Breast Cancer Clinical Trials Program, Division of Hematology-Oncology
    David Geffen School of Medicine, UCLA
    Santa Monica, CA 

    Contracted Research: Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi-Sankyo, Dignitana, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Pfizer, Phoenix Molecular Designs, Ltd., Pieris, Puma, Radius, Samumed, Sanofi, Seattle Genetics, Zymeworks
    Ownership Interest: NKMax; (spouse): ROMTech, Ideal Implant

    Nancy Lin, MD
    Associate Professor of Medicine
    Dana-Farber Cancer Institute/Harvard Medical School
    Boston, MA

    Advisory Board: Puma, Seattle Genetics, Voyager Therapeutics
    Consulting Fees: Affinia Therapeutics, Aleta BioPharma, AstraZeneca, Daiichi Sankyo, Denali Therapeutics, Olema Pharmaceuticals, Pfizer, Prelude Therapeutics
    Research: AstraZeneca, Genentech, Merck, Pfizer, Zion Pharmaceuticals
    Royalities: UpToDate

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Nicole Fox, DNP, MSN-Ed, RN, OCN, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objective

    After participating in this educational activity, participants should be better able to:

    • Compare and contrast the latest evidence to incorporate optimal therapies into clinical practice in the HER2-positive MBC setting  
  • Target Audience

    This activity is designed to meet the educational needs of community medical oncologists, academic medical oncologists, and pathologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, and Seagen.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free